UNSPSC 51431509: Tirofiban hydrochloride monohydrate

This classification denotes an antiplatelet agent with the molecular formula C22H36N2O5S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6H925F8O5J, chemically known as l-tyrosine, n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-, hydrochloride, hydrate (1:1:1), but more generally known as tirofiban hydrochloride monohydrate, which bears US NIH Compound Identifier 60946.

European Medicines Agency schedules tirofiban hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11118MIG. Most nations, for tariff purposes, schedule tirofiban hydrochloride monohydrate under HS 29350090. SMILES: CCCCS(=O)(=O)N[C@@H](CC1CCC(CC1)OCCCCC2CCNCC2)C(=O)O.O.CL.

UNSPSC 51431509 Tirofiban hydrochloride monohydrate is a Commodity code that in practice encompasses a narrow range of advanced life support and specialty pharmaceuticals procured by state and local health systems, fire rescue departments, and pharmacy benefit programs. State and local governments buy this medication primarily as a component of broader emergency medical supply contracts or as part of larger pharmaceutical procurement initiatives that include multiple medication line items. Issuing bodies include city fire rescue departments (Tampa Fire Rescue through the City of Tampa), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance) that aggregate demand across participating jurisdictions. The work being solicited is primarily goods procurement — sealed bids for inventory replenishment with firm pricing, delivery timelines measured in days to weeks, warranty of product integrity, and management of expiration dates and replacement logistics.

Activity under this code appears concentrated in the South and Upper Midwest, with recent solicitations from Florida, Texas, and Minnesota through early 2026. The City of Tampa Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026, estimated value $40,000) requiring supply of Labetalol, Epinephrine, Adenosine, and Diltiazem with a one-year contract term and SLBE sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) as a preliminary market intelligence phase exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration, through MMCAP, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with evaluation weighted 75 percent on price competitiveness and contract terms effective July 1, 2026. The code shows modest recent activity with issuing bodies spanning municipal emergency services, state health agencies, and cooperative purchasing vehicles.